Global stock

NASDAQUSD

Amgen Inc.

AMGN

AI analysis and articles are in Czech.

§ Financial healthLong-term stability

60/ 100

Overall score·AMGN

Current price

449.02USD

26/10/2026

P/E, P/B

Valuation

Neutral

Rates whether the stock is cheap or expensive relative to its history and sector. A score above 60 suggests the stock trades below its estimated intrinsic value.

Tracks:P/E · P/B · FCF yield · sector

Forward P/E 17,7 je příznivější než současné P/E 26,9, zatímco PEG 2,58 a P/B 20 ukazují na náročnější ocenění; valuace je proto smíšená. Silnými stránkami jsou vysoké marže a růst EPS, slabší stránkou je výrazné zadlužení vůči vlastnímu kapitálu. Cena je nad 50denním i 200denním průměrem, ale zaostává za uvedeným cílem analytiků.

§ Outlook vs S&P 500Next 12 months

About the same

Estimated chance of beating the index: about 48%

8 of 8 inputs

NoProbably notSameProbably yesYes

A model estimate from current values. The result may change with new data; it is not a price target or an investment recommendation.

§ Metrics summary

A quick look at Amgen Inc. (AMGN) combining financial health, the short-term signal, valuation, DCF, management quality and operating metrics. It is analytical context, not a recommendation to buy or sell.

60/100

The overall score is based mainly on long-term fundamentals, complemented by the current signal and the available qualitative rating of the company.

68/100

Slightly positive signal based on current news, price action and the economy.

39/100

A lower score means the stock is expensive relative to the company's earnings and assets.

63% above fair value

An estimate of what the stock should be worth based on the company's future cash.

+10%

How fast the company's revenue grows year on year.

78/100

How much the company earns from each unit of revenue and from invested capital.

52/100

Debt level, share-price volatility and how resilient the company is in bad times.

70/100

AI estimate of management quality, execution and capital allocation.

82/100

AI estimate of the company's durable competitive advantage.

§ Context and events

Management

Předsedou představenstva a generálním ředitelem je Robert A. Bradway. Murdo Gordon vede globální trhy a oblast veřejné politiky, Peter H. Griffith je výkonným viceprezidentem a James E. Bradner vede výzkum a vývoj, včetně umělé inteligence a dat. Strategie společnosti stojí na vývoji inovativních léčiv, rozšiřování portfolia a komercializaci biologických přípravků.

Articles about Amgen Inc., in Czech (1)

WidePoint těží z vládního kontraktu, Blackstone přitahuje zájem investorů, Amgen čelí možnému stažení léku v EU

WidePoint zaznamenal prudký růst akcií po oznámení o kontraktu s DHS v hodnotě 3 miliardy dolarů, zatímco Blackstone Secured Lending Fund láká investory vysokým výnosem 13 %. Naopak, Amgen čelí nejistotě kvůli doporučení EU stáhnout lék Tavneos z trhu.

26 June 2026· 4 min

§ Upcoming results

3 November 2026

in 7 days

Earnings

Earnings = quarterly financial results (revenue and profit). Companies publish them every three months and the share price often reacts strongly.

§ Frequently asked questions

What is Amgen Inc. (AMGN)?

Amgen Inc. (AMGN) is a global stock traded on NASDAQ. Sector: Healthcare. We track it daily — scoring news sentiment, the short-term outlook and long-term stability on a 0–100 scale.

What is the Amgen Inc. price today?

As of 26 October 2026, Amgen Inc. trades at about 449.02 USD per unit. We update the price daily from public market data. Intraday moves can differ significantly — always check the final price with your broker.

How to buy Amgen Inc.?

Through regulated online brokers such as Degiro, XTB, Trading 212 or Interactive Brokers. Shares trade in USD or EUR — most brokers convert your currency automatically. FinSignal does not operate any of these platforms and charges no commission — the overview is only a signpost.

Does Amgen Inc. pay a dividend?

Amgen Inc. either pays no dividend at the moment or we have no reliable data on it. Many growth companies prefer reinvesting profit to paying dividends — check the current policy in the company's investor relations materials.

Is Amgen Inc. a good investment in 2026?

Our AI signal currently rates Amgen Inc. as slightly positive (score 68/100). Financial health comes out at 60/100, so beyond short-term news it is worth watching the valuation, growth, profitability and stability of the company. The DCF model currently puts the price about 63 % above its model fair value. FinSignal is not an investment adviser licensed under Czech Act No. 256/2004 Coll. — signals are analytical input, not a recommendation to buy or sell. You make every decision at your own risk.

§ More global stocks

Microsoft Corporation

MSFThealth 73/100

§ How to buy Amgen Inc.

You can buy shares through regulated online brokers available in the EU. They differ mainly in fees, app quality and which markets they cover.

Degiro
Dutch broker with low fees for passive investors. No account fee, trading in EUR and USD.
XTB
Polish broker with zero commission on stocks and ETFs up to EUR 100,000 a month. Own xStation platform.
Trading 212
Zero-commission broker with fractional shares from EUR 1 and automated investing (Pies). Suits beginners and regular investing.
Interactive Brokers
US broker for advanced investors. The widest choice of markets, low costs at larger volumes, a professional platform with a steeper learning curve.

FinSignal operates none of these platforms. We charge no commission on purchases.

Important: Signals are an analytical tool, not investment advice within the meaning of Czech Act No. 256/2004 Coll. Past performance does not guarantee future results. You make all decisions at your own risk.

§ Current signalShort-term mood

/ 100

● Slightly positive

Earnings in 7 days

On 3 November 2026 the company publishes its quarterly results. This period tends to bring large price moves.

News summary

Older news

Signal 26/10, 18:01

Na ESMO 2026 Amgen představil podle zprávy „bezprecedentní“ data; rozsah přínosu může podpořit výhled, pokud jej potvrdí další klinické výsledky. Jefferies zvýšil cílovou cenu na 428 USD z 410 USD.

Růst o 5,67 % za týden a 8,3 % za měsíc spolu s rostoucím trendem podporují krátkodobý výhled. RSI 71 a vysoká volatilita ale zvyšují možnost korekce; dlouhodobě pomáhá vývojové portfolio firmy.

Risks: Pokud se růst ceny obrátí nebo klinická data nenajdou potvrzení v dalších studiích, pozitivní výhled může zeslábnout.

More about the signal

Risks: Pokud se růst ceny obrátí nebo klinická data nenajdou potvrzení v dalších studiích, pozitivní výhled může zeslábnout.

Signal history· 2

25/1011:0164 · Slightly positive
Amgen za poslední měsíc posílil o 8,18 %, přestože 23. října klesl o 1,79 % a zaostal za širším trhem; udržení růstového trendu by výhled podpořilo.
25/1002:0172 · Strongly positive
Amgen podle zprávy zveřejnil pozitivní výsledky fáze 3 Tezspire u eozinofilní ezofagitidy; širší klinický přínos podpoří výhled, pokud se potvrdí v dalším vývoji.

The full 90-day signal history is part of Premium.

Ask the AI

§ Model fair value (DCF)

Overvalued63% above fair value

275.37

range 218.9 – 355.3

Current price

449.02 USD

26 Oct 26

PriceFair value range (DCF)UndervaluedOvervalued

What the calculation is based on

Model

275.37 USD

range 218.9 USD – 355.3 USD

: 6.0%
: 9.0%
: 15.03 USD

Růst FCF 6 % p.a. je konzervativní předpoklad pro zavedenou biotechnologickou společnost; aktuální růst EPS může být mimořádný a nemusí se opakovat. Diskontní sazba 9 % zohledňuje stabilní charakter podnikání i rizika spojená s vysokým zadlužením.

DCF terms explained+

DCF (discounted cash flow) estimates how much cash the company will generate in the future and converts it into today's value per share.

Free cash flow (FCF) is the money left after running the business and investing. “12 m” means the last 12 months.

The discount rate expresses risk: the riskier the company, the higher the rate and the lower the fair value.

Fair value is a model estimate — not the market price and not an investment recommendation.

With Premium you can adjust growth, the discount rate and free cash flow, and the fair value recalculates live.

Adjust assumptions14 days free →

A model estimate, not an investment recommendation. Past performance does not guarantee future results.

§ Valuation check

Is the price reasonable?

Six quick tests: price against fair value, the last year, similar companies and analyst estimates. They are calculated from the numbers, not from AI estimates. This is not a recommendation.

Data 18 of 18

Valuation score

0/ 6

6/6 tests available

1. Below DCF fair value

63.1% above the DCF midpoint.

2. Well below DCF value

Discount = below the range or at least 15% below the midpoint.

3. Price vs. the last year

100% above the 1-year low (320.7 USD to 449.0 USD), based on stored daily prices.

4. P/E vs. similar companies

P/E 26.9 vs. median 26.4 (71 companies).

5. P/E relative to growth

PEG 2.6; a lower value means cheaper growth.

6. Analyst price target

-12.0% vs. the current price, 29 analysts.

Price vs DCF

Current price

449.0 USD

Low 218.9 USDHigh 355.3 USD

Current priceDCF midpoint: 275.4 USD

Price vs analyst target

Current price

449.0 USD

Low 225.0 USDHigh 500.0 USD

Current priceAverage: 395.0 USD

DCF gap

above range

63.1% above the DCF midpoint (275.4 USD).

Analyst target

-12.0%

Average target 395.0 USD vs. price 449.0 USD.

Analyst consensus

Target range

225.0 USD - 500.0 USD

Coverage

29 analysts

Analyst consensus

2.7 / 5

Changes 180 d

+0 / -2

EPS next year

6.4%

Revenue next year

3.6%

Valuation multiples

26.9

17.7

6.1

16.1

2.6

52-week range100% above the low

320.7 USD449.0 USD

65.0%

10.0%

23.0%

91.5%

Price vs 50D8.2%

Price vs 200D21.7%

Metrics explained+

Price and fair value

DCF range: A model estimate of fair value from future free cash flow. A price above the range means the market pays a premium over the model; a price below it may signal a more conservative market valuation or an overly optimistic model.
Analyst target: The average and range of the analyst price targets we track. It is the market consensus, not a FinSignal recommendation, and it can lag fast price moves.
52-week range: Shows where the current price sits between the low and high of the last year. A value near the high often signals strong momentum, but on its own says nothing about whether the stock is expensive.
Price vs 50D / 200D: Compares the price with its short- and long-term moving averages. A positive value means the price is above the trend; a negative one below it.

Multiples

P/E: Price relative to current earnings. A lower P/E can mean cheaper, but it can also point to a weak outlook or risk.
Forward P/E: Price relative to next year's expected earnings. For growing companies it is often more useful than the historical P/E because it reflects estimates of future earnings.
P/B: Price relative to the book value of equity. It makes more sense for banks, insurers and capital-intensive companies than for software or brands.
P/S: Price relative to revenue. It helps with companies that have low or negative earnings; a high P/S means the market expects strong growth or future margins.
EV/EBITDA: The value of the whole company, including debt, relative to operating profit before depreciation. Useful for comparing companies with different leverage.
PEG: P/E adjusted for earnings growth. A value around 1 may suggest the valuation matches growth, but the metric is sensitive to estimates.

Growth and quality

EPS growth: Year-on-year change in earnings per share. Strong growth supports a higher valuation, but for cyclical companies it can be temporary.
Revenue growth: The growth rate of sales. It helps tell whether profits grow on real demand or mainly on cost savings.
Net margin: How much of each unit of revenue is left as net profit. A higher margin often points to stronger pricing power or more efficient operations.
ROE: Return on equity. A high ROE can signal a quality business, but check that it is not artificially boosted by heavy debt.

Most data available. Missing values mean the market data source did not provide them for this ticker. The data is indicative and may be delayed. Price as of 26/10/2026.

Management and competitive advantage

Both are estimated by the AI from the company profile, news and results. They do not count towards the 6-pillar financial health score. The AI comments are in Czech.

strong

Vedení má zkušenosti s řízením velké farmaceutické společnosti a strategicky rozvíjí výzkum, přičemž governance riziko je podle dodaných údajů celkově nízké. Hodnocení mírně snižují slabší dílčí skóre auditu a představenstva.

strong

Amgen těží z rozsáhlého portfolia biologických léčiv, zavedených značek, patentů a globální obchodní infrastruktury. Konkurenční výhodu částečně oslabují patentová rizika, cenový tlak a konkurence dalších farmaceutických společností.

Information

Type: Global stock
Symbol: AMGN
Exchange: NASDAQ
Currency: USD
Sector: Healthcare
: 26.9x
: 233.8B USD
: 490.3 %
: 0.41

§ Risk profile

Výnosy mohou ovlivnit ztráta patentové ochrany, konkurence biosimilárních léků, neúspěšné klinické studie a tlak na ceny léčiv. Českému investorovi se navíc výsledek v korunách mění podle kurzu dolaru.

Ask the AI about Amgen Inc.All signals